A 9-year-old female patient is evaluated in the pediatric acute care unit due to progressi… — USMLE Step 2 CK

A $9$ -year-old female patient is evaluated in the pediatric acute care unit due to progressive dyspnea that began yesterday. She has a documented history of moderate persistent asthma, currently managed with a daily inhaled corticosteroid and a short-acting beta-agonist as needed. Over the previous $24$ hours, she has required her rescue inhaler every two hours with minimal relief. Vital signs on presentation show a temperature of $37.0^\circ\text{C}$ ( $98.6^\circ\text{F}$ ), blood pressure of $110/70\text{ mm Hg}$ , heart rate of $142/\text{min}$ , and respiratory rate of $44/\text{min}$ . Oxygen saturation is $91\%$ on ambient air. The patient appears highly anxious, sits leaning forward, and speaks only in two-word phrases. Examination highlights significant intercostal and suprasternal retractions. Auscultation of the chest reveals widespread tight wheezing and notably reduced air entry in all lung fields. Supplemental oxygen is applied, and the patient receives a systemic dose of intravenous methylprednisolone alongside three back-to-back treatments of nebulized albuterol combined with ipratropium bromide. One hour later, reassessment shows a heart rate of $150/\text{min}$ and a respiratory rate of $40/\text{min}$ . She remains awake and responsive but continues to exhibit severe accessory muscle use and diminished breath sounds. Which of the following is the most appropriate next step in management?

Administration of intravenous magnesium sulfateAnswer
B
Administration of intravenous ceftriaxone
C
Administration of nebulized hypertonic saline
D
Administration of intravenous furosemide
E
Administration of nebulized racemic epinephrine

Answer

Administration of intravenous magnesium sulfate

The correct answer is the administration of intravenous magnesium sulfate. This patient is presenting with a severe asthma exacerbation that is refractory to standard initial management (inhaled short-acting beta-agonists, inhaled anticholinergics, and systemic corticosteroids). In pediatric patients with severe, unresponsive asthma exacerbations, intravenous magnesium sulfate is the most appropriate next step. It acts as a smooth muscle relaxant by competitively blocking calcium channels, leading to bronchodilation. It is proven to improve pulmonary function and reduce hospital admission rates in children with severe acute asthma.

Step-by-Step Solution

Evaluate the severity of the patient's presentation.

The patient is experiencing a severe asthma exacerbation, characterized by tachypnea, hypoxia, use of accessory muscles, limited speaking ability, and decreased air entry.

Accurate severity classification dictates the initial aggressiveness of treatment.

Assess the response to initial therapy.

Despite receiving supplemental oxygen, systemic corticosteroids, and three consecutive nebulized bronchodilator treatments (albuterol/ipratropium), the patient remains in severe respiratory distress.

Failure to improve with first-line therapy indicates a refractory exacerbation requiring escalation.

Determine the next pharmacological intervention.

Intravenous magnesium sulfate should be administered.

IV magnesium sulfate is a well-established adjunct therapy that induces bronchodilation by inhibiting calcium influx into smooth muscle cells. It is indicated in children with severe asthma exacerbations who do not adequately respond to initial intensive therapy, helping to prevent the need for intubation.

Key Concept

Management of refractory severe asthma exacerbations in pediatric patients

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic